The SARS-CoV-2 Vaccine Pipeline: an Overview

Current Tropical Medicine Reports

Volumn 7, Issue 2, 2020, Pages 61-64

  Chen, Wen Hsiang ^a   Strych, Ulrich ^a   Hotez, Peter J ^a   Bottazzi, Maria Elena ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Coronavirus; COVID 19; RBD; Receptor binding domain; Wuhan virus

Indexed keywords

ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR; DNA VACCINE; LIVE VACCINE; MESSENGERRNA VACCINE; RECOMBINANT VACCINE; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CORONAVIRUS DISEASE 2019; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; IMMUNOPOTENTIATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VACCINATION; VIRUS TRANSMISSION;

EID: 85081614187     PISSN: None     EISSN: 21963045     Source Type: Journal    
DOI: 10.1007/s40475-020-00201-6     Document Type: Review

References (26)

1. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. 10.1056/NEJMoa2001316.
2. World Health Organization. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020. 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed February 13, 2020.
3. Rothe C, Schunk M, Sothmann P, Bretzel G, Froeschl G, Wallrauch C, et al. Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. N Engl J Med. 2020. 10.1056/NEJMc2001468.
4. Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. bioRxiv. 2020:2020.01.31.929042. doi:10.1101/2020.01.31.929042.
5. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv. 2020:2020.01.22.914952. doi:10.1101/2020.01.22.914952.
6. Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Hu Y et al. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv. 2020:2020.01.24.919183. doi:10.1101/2020.01.24.919183.
7. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012;11(12):1405–13. 10.1586/erv.12.126. DOI: 10.1586/erv.12.126
8. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. 10.1016/S0140-6736(20)30183-5.
9. Pong W. A dozen vaccine programs under way as WHO declares coronavirus public health emergency. Biocentury. 2020. https://www.biocentury.com/article/304328/industry-and-academic-centers-are-rushing-to-create-new-vaccines-and-therapeutics-targeting-coronavirus. Accessed 28 Feb 2020.
10. Novel Coronavirus. @jnjnews. 2020. https://www.jnj.com/coronavirus. Accessed February 10, 2020.
11. BioSpace. Codagenix and Serum Institute of India Initiate Co-Development of a Scalable, Live-Attenuated Vaccine Against the 2019 Novel Coronavirus, COVID-19. 2020. https://www.biospace.com/article/releases/codagenix-and-serum-institute-of-india-initiate-co-development-of-a-scalable-live-attenuated-vaccine-against-the-2019-novel-coronavirus-covid-19/. Accessed 2/13/2020.
12. Hennessy J. Australia’s been asked to make a coronavirus vaccine at ‘unprecedented speed’. Science Alert. 2020. https://www.sciencealert.com/australian-scientists-asked-to-make-coronavirus-vaccine-at-unprecedented-speed. Accessed 28 Feb 2020.
13. Pharmaceutical Technology N. Coronavirus: Vir Biotechnology and Novavax announce vaccine plans. 2020. https://www.pharmaceutical-technology.com/news/coronavirus-vir-biotechnology-novavax-vaccine/. Accessed 28 Feb 2020.
14. Clover Biopharmaceuticals. Clover initiates development of recombinant subunit-trimer vaccine for Wuhan coronavirus (2019-nCoV). 2020.
15. Mukherjee S. The first coronavirus drug candidate is set for testing in China. Fortune. 2020. https://fortune.com/2020/02/03/coronavirus-vaccine-testing-in-china/. Accessed 28 Feb 2020.
16. Vaxart. PipelineReview.com Vaxart Announces Initiation of Coronavirus Vaccine Program. 2020. https://pipelinereview.com/index.php/2020020273689/Vaccines/Vaxart-Announces-Initiation-of-Coronavirus-Vaccine-Program.html. Accessed 28 Feb, 2020.
17. Inovio Pharmaceuticals. Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China. 2020. http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Collaborating-With-Beijing-Advaccine-To-Advance-INO-4800-Vaccine-Against-New-Coronavirus-In-China/default.aspx. Accessed 28 Feb 2020.
18. Park A. Inside the Company That's Hot-wiring Vaccine Research in the Race to Combat the Coronavirus. Time. 2020. https://time.com/5775784/coronavirus-vaccine-research/. Accessed 28 Feb 2020.
19. Smith J. CureVac bids to develop first mRNA coronavirus vaccine. 2020. https://www.labiotech.eu/medical/curevac-coronavirus-outbreak-cepi/. Accessed 28 Feb 2020.
20. J&J working on coronavirus vaccine. thepharmaletter 2020. https://www.thepharmaletter.com/article/j-j-working-on-coronavirus-vaccine. Accessed 28 Feb 2020.
21. ClinicalTrials.gov. National Institutes of Health. https://clinicaltrials.gov/ct2/show/NCT02543567. Accessed February 7, 2020.
22. Cheung E. China coronavirus: Hong Kong researchers have already developed vaccine but need time to test it, expert reveals. South China Morning Post. https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have. Accessed 28 Feb 2020.
23. Shieber J. Codagenix raises $20 million for a new flu vaccine and other therapies. Tech Crunch. https://techcrunch.com/2020/01/13/codagenix-raises-20-million-for-a-new-flu-vaccine-and-other-therapies/. Accessed 28 Feb 2020.
24. Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32(26):3169–74. 10.1016/j.vaccine.2014.04.016.
25. Chen WH, Chag SM, Poongavanam MV, Biter AB, Ewere EA, Rezende W, et al. Optimization of the production process and characterization of the yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1), a SARS vaccine candidate. J Pharm Sci. 2017;106(8):1961–70. 10.1016/j.xphs.2017.04.037. DOI: 10.1016/j.xphs.2017.04.037
26. Chen WH, Du L, Chag SM, Ma C, Tricoche N, Tao X, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccines Immunother. 2014;10(3):648–58. DOI: 10.4161/hv.27464